Discounted Cash Flow Rating

Strong Sell

Return on Equity Rating

Strong Sell

Debt to Equity Rating

Neutral

Price to Earnings Rating

Strong Sell

Analyst Rating

Sell

Upgrade To View Simple Moving Average Rating

Upgrade

Upgrade To Get Access

Upgrade To View Exponential Moving Average Rating

Upgrade

Upgrade To Get Access

Upgrade To View Relative Strength Index Rating

Upgrade

Upgrade To Get Access

Upgrade To View Standard Deviation Rating

Upgrade

Upgrade To Get Access

Upgrade To View Williams %R Rating

Upgrade

Upgrade To Get Access

Upgrade To View Average Directional Index Rating

Upgrade

Upgrade To Get Access

Upgrade To View Insider Trading Rating

Upgrade

Upgrade To Get Access

Wall Street Data Solutions Rating

Neutral

B

Zymeworks Inc. (ZYME)

Pharmaceutical Preparations

https://www.zymeworks.com

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of differentiated product candidates. Its clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

108 PATRIOT DRIVE, SUITE A
MIDDLETOWN, DE

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

04/28/2017

Market Cap

750,971,018

Shares Outstanding

70,000,000

Weighted SO

70,001,987

Total Employees

N/A

Upcoming Earnings

08/01/2024

Similar Tickers

DAWN --.--%

INZY --.--%

ZNTL --.--%

SNDX --.--%

PTGX --.--%

RVMD --.--%

BPMC --.--%

STOK --.--%

CYTK --.--%

Beta

1.1420

Last Div

0.0000

Range

6.015-13.14

Chg

0.0700

Avg Vol

650879

Mkt Cap

750971018

Exch

NYSE

Country

CA

Phone

16046781388

DCF Diff

20.1649

DCF

-9.6049

Div Yield

0.0000

P/S

11.9763

EV Multiple

-6.2756

P/FV

1.9881

Div Yield %

0.0000

P/E

-7.1770

PEG

-1.5299

Payout

0.0000

Current Ratio

7.0092

Quick Ratio

7.0092

Cash Ratio

1.2970

DSO

186.7405

DIO

0.0000

Op Cycle

186.7405

DPO

6.7696

CCC

179.9709

Gross Margin

-0.4901

Op Margin

-1.9147

Pretax Margin

-1.8496

Net Margin

-1.7942

Eff Tax Rate

0.0491

ROA

-0.2182

ROE

-0.2596

ROCE

-0.2605

NI/EBT

0.9701

EBT/EBIT

0.9660

EBIT/Rev

-1.9147

Debt Ratio

33.3470

D/E

42.3350

LT Debt/Cap

0.9769

Total Debt/Cap

0.9769

Int Coverage

-16.6333

CF/Debt

-0.0053

Equity Multi

1.2695

Rec Turnover

1.9546

Pay Turnover

53.9175

Inv Turnover

0.0000

FA Turnover

1.7540

Asset Turnover

0.1216

OCF/Share

-1.1903

FCF/Share

-1.2508

Cash/Share

4.3217

OCF/Sales

-1.4501

FCF/OCF

1.0509

CF Coverage

-0.0053

ST Coverage

-32.0284

CapEx Coverage

-19.6534

Div&CapEx Cov

-19.6534

P/BV

1.9881

P/B

1.9881

P/S

11.9763

P/E

-7.1770

P/FCF

-7.8590

P/OCF

-8.8803

P/CF

-8.8803

PEG

-1.5299

P/S

11.9763

EV Multiple

-6.2756

P/FV

1.9881

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Jan 04, 06:15 Zymeworks Outlines Strategic Priorities and Outlook for 2024 and 2025 GlobeNewswire Inc. Dec 15, 08:30 Zymeworks Added to Nasdaq Biotechnology Index GlobeNewswire Inc. Nov 01, 08:30 Zymeworks Announces Participation in Upcoming Investor Conferences

Revenue Product Segmentation